The United States pays higher prices for prescription drugs than any of its peers — about 250% of the price paid on average by other Organization for Economic Cooperation and Development countries, according to a recent report from the Rand Corp.
House Democrats writing the health provisions of their big social spending bill aimed high: new coverage for poor Americans without insurance; extra subsidies for people who buy their own coverage; and new dental, hearing and vision benefits for older Americans through Medicare. To pay for those, they also aimed high when it came to lowering drug prices . A measure that would link the prices of certain prescription drugs to those paid overseas was devised to save the government enough money to of
A Democratic plan to reduce drug prices stalled on Wednesday in the House Energy and Commerce Committee. (AP)Margot Sanger-KatzSeptember 16, 2021, 9:04 PM·5 min readHouse Democrats writing the health provisions of their big social spending bill aimed high: new coverage for poor Americans without insurance; extra subsidies for people who buy their own coverage; and new dental, hearing and vision benefits for older Americans through Medicare.
To pay for those, they also aimed high when it came to lowering drug prices. A measure that would link the prices of certain prescription drugs to those paid overseas was devised to save the government enough money to offset the costs of those other priorities. The House approach, estimates suggest, could save the government around $500 billion over a decade, with that money coming out of the pockets of the pharmaceutical industry.
Sign up for The Morning newsletter from the New York TimesBut it is risky to bet against the drug companies.Three House Democrats on a key committee voted against the measure Wednesday. There are still ways for House leaders to keep the provision in the final bill, but the House Democratic majority is so slim that those three legislators, if determined, could represent a significant barrier to passing the broader package. headtopics.com
The dynamic is familiar to lawmakers who have worked on health issues: Health industries are large and powerful lobbies, and they do not enjoy having their revenues cut. As with measures that might reduce payments to hospitals, doctors and insurance companies, the House’s attempt to take a bite out of drug companies has generated a backlash.
“I just don’t think paying for a lot of things by crippling investments in life sciences is really the way to go forward,” Rep. Scott Peters, D-Calif., told The New York Times on Tuesday. “Losing the investment in pharma is too big a price to pay.” (Reps. Kurt Schrader of Oregon and Kathleen Rice of New York are the other House Democrats who voted against the measure.)
Peters’ district in the San Diego area includes tens of thousands of workers in medical research and drug development. Some might lose their jobs if pharmaceutical profits shrank, research investments dwindled or companies closed their doors. Peters has co-sponsored a competing drug pricing bill, which he argues would better target inefficiencies and market failures. The budgetary effects of that legislation have not been measured — and the House committee did not vote on it Wednesday — but it is similar to a Senate bill that was estimated to generate one-fifth as much savings.
Story continuesWithout the drug pricing provision, Democrats will have a tough time financing their other priorities. They are passing their bill using a special budget procedure to avoid a Republican filibuster. But that process means their bill has to hit specified budget targets. If the money saved from drug price regulation is reduced, so too is the pot of money that can be spent on other goals. Democrats have already abandoned plans for some other revenue-generating policies, like a wealth tax. headtopics.com
The United States pays higher prices for prescription drugs than any of its peers — about 250% of the price paid on average by other Organization for Economic Cooperation and Development countries, according to a recent report from the Rand Corp. And those high costs ripple through the federal budget and the economy, increasing insurance premiums and putting lifesaving medications out of reach for some patients.
Democrats in Congress want to lower the drug prices that Medicare and other insurers pay, both to generate a way to pay for other things and also to benefit general consumers and businesses.But lowering drug prices does come with trade-offs. Drug company businesses are built around assumptions of high margins in U.S. markets, and investors in early-stage companies make choices based on their expectation that a drug that works will generate a big payday. The Congressional Budget Office — the same nonpartisan agency that told the House such a policy could save the federal government lots of money — recently released a report indicating that substantial drug price reductions would have corresponding negative effects on the number of new drugs developed in the future.
Naturally, the pharmaceutical industry is not happy about the prospect of large price cuts. Steve Ubl, CEO of the industry trade group PhRMA, described the measure last week as “existential” to his industry. He also said it was unfair that drug companies alone were being asked to shoulder the costs of such a large health care expansion.
“We’re being asked to pay a disproportionate share of the bill,” he said.The drug industry has spent years donating to political campaigns, lobbying members of Congress and developing allies in the business community. They are now urgently leveraging those relationships. PhRMA announced a “seven-figure” advertising buy Wednesday and published an open letter in several Washington publications, adding to television ads running on national news programs and football broadcasts. headtopics.com
It is a playbook that other powerful health lobbies have used. Groups representing doctors, hospitals and private equity firms started an enormous campaign in 2019 to defeat bipartisan legislation to ban the practice of surprise medical billing. Their efforts stopped the ban, though Congress ultimately passed a more industry-friendly version a year later.
Leaders in the Senate have signaled that they want to pursue their own approach to drug price regulation. Whether their measure will differ in the policy fine print or in the magnitude of the cut to pharmaceutical profits remains to be seen. But the House has been generally perceived as more aggressive on the issue. Its difficulties this week could signal a softer approach and perhaps a smaller budget for Congress and the White House’s other lofty goals.
© 2021 The New York Times CompanyOur goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commentingRecommended StoriesGM tells Bolt EV owners to park 50 feet away from other vehicles
General Motors Co on Wednesday recommended that Chevrolet Bolt electric vehicle owners parking in public garages do so on the top floor or on an open level, and at least 50 feet away from other vehicles, citing potential fire risks. GM sent a notice to consumers who had asked about parking issues, he added. GM had previously asked owners to park Bolt vehicles outdoors, away from structures, and to not charge them overnight.
1d agoDemocratic moderates are Biden's big Capitol Hill headacheJoe Biden has spent the vast majority of his half century in politics marketing himself as a pragmatic Democratic moderate. Yet some eight months into his presidency, his party’s centrist wing has become a major roadblock to passing his ambitious domestic policy agenda.Read more: Yahoo News »
Hubble Finds Evidence of Water Vapor in One Hemisphere of Europa
NASA’s Hubble Space Telescope observations of Jupiter’s icy moon Europa have revealed the presence of persistent water vapor – but, mysteriously, only in one hemisphere.
It’s not “power” of the industry but the corruption of lawmakers that is on display.
Democrats' sweeping healthcare expansion at risk amid new clash over drug pricingDemocrats are sharply divided over whether to require drugmakers to negotiate their prices with the federal government. good Even Democrats know this is a bad idea.
Column: Drugmakers see disaster in Medicare negotiating prices. Don't listen to them'The pharmaceutical industry , bizarrely, told the American people this week that allowing Medicare to negotiate drug prices is tantamount to socialism, rather than an example of a healthy, competitive marketplace.' Column by Davidlaz: YvannaCancela Davidlaz I call BS. Davidlaz Rich people tend to proclaim anything that helps the poor and working types as 'socialism.' Just a bunch of squawking. 🤷♂️ good luck
Centrist Democrats scramble House drug pricing effortThree centrist House Dems threw their party's health care agenda into disarray today by blocking a plan that would have authorized direct government negotiation of drug prices and help pay for a $3.5 trillion social spending bill This is not a centrist position on drug pricing They aren’t centrist Dems, they’re Dems with deep financial ties to drug companies, but that would disrupt your precious narrative Why do Dems hate people and even bother to pretend to serve any one other than their corporate overlords?
On’s IPO Is A ‘Starting Line’ For The Fastest-Growing Athletic Shoe Brand In U.S.Launched in 2010 by Olivier Bernhard, Caspar Coppetti and David Allemann with the brand's unique CloudTec technology for running, the distinct outsole technology quickly caught on in the running community with the Cloud silhouette and the brand immediately expanded out of Switzerland. LOVE EACHOTHER! SHARE THE LOVE! wow Hayaalroumi187
Column: Surging European gas prices to drive down pre-winter demand: KempEuropean gas prices are surging on tight inventories heading into winter, incentivising power producers to switch back to coal and industrial users to consider temporary plant closures. 👍👍👍 good luck Damn Bidens controlling gas in Europe. Where does it end
UK inflation rate posts biggest increase since records beganThe U.K.'s consumer prices index surged by 3.2% in the 12 months to August, official data showed on Wednesday, the largest ever month-on-month increase since records began. good luck But we good tho Dominoes are falling